fda glp-1 compounding enforcement september 2025 Beyond the Headlines: Warning Letters to Compounders FDA issued 25 warning letters

Furthermore, targeted knockdown of GLP-1 Rs in the medial habenula (MHb) or pharmacological antagonism in the interpeduncular nucleus (IPN) increases nicotine consumption and reinstates preference for nicotine-paired environments (Tuesta et al., 2017)

The battle over semaglutide Eli Lilly reported stellar third-quarter earnings yesterday and raised this years revenue estimates from $60 billion$62 billion to $63 billion$63.5 billion, crediting the growing adoption of its weight loss drugs Zepound and Mounjaro

While behavioral changes during treatment help, the underlying metabolic drive to regain weight typically persists, making long-term therapy more effective than short-term use

A weight-loss coordinator will reach out within one business day

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

Important warnings include thyroid tumor risk, pancreatitis, gallbladder disease, dehydration-related kidney injury, and hypoglycemia when used with insulin or sulfonylureas